ABI-009
Product
Aadi Bioscience, Inc.
Total Payments
$511,356
Transactions
40
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $511,356 | 40 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $511,356 | 40 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | Aadi Bioscience, Inc. | $452,488 | 0 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | Aadi Bioscience, Inc. | $58,869 | 0 |
Top Doctors Receiving Payments for ABI-009
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Englewood, NJ | $511,356 | 40 |
Ad
Manufacturing Companies
- Aadi Bioscience, Inc. $511,356
Product Information
- Type Product
- Total Payments $511,356
- Total Doctors 0
- Transactions 40
About ABI-009
ABI-009 is a product associated with $511,356 in payments to 0 healthcare providers, recorded across 40 transactions in the CMS Open Payments database. The primary manufacturer is Aadi Bioscience, Inc..
Payment data is available from 2022 to 2022. In 2022, $511,356 was paid across 40 transactions to 0 doctors.
The most common payment nature for ABI-009 is "Unspecified" ($511,356, 100.0% of total).
ABI-009 is associated with 2 research studies, including "A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes." ($452,488).